Identification of two pathogenic guanidinoacetate methyltransferase variants in patients with intellectual disability: clinical and molecular insights
5 affiliations
- 1Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
- 2Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
- 3Pediatric Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
- 4Meybod Genetic Research Center, Meybod, Yazd, Iran
- 5Abortion Research Center, Yazd Institute of Reproductive Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract
Background: Intellectual disability (ID) is a genetically heterogeneous neurodevelopmental disorder with diverse underlying causes. Guanidinoacetate methyltransferase (GAMT) deficiency is a rare autosomal recessive disorder of creatine biosynthesis characterized by cerebral creatine depletion and accumulation of guanidinoacetate (GAA), resulting in a spectrum of neurodevelopmental manifestations, including intellectual disability. This study aimed to investigate the molecular basis of ID in individuals with suspected genetic etiologies and to characterize pathogenic GAMT variants.
Methods: Whole-exome sequencing (WES) was performed in 50 unrelated Iranian individuals with idiopathic ID. Variants were prioritized based on population allele frequency, predicted functional impact, and genotype–phenotype correlation. Candidate variants were confirmed by Sanger sequencing, and segregation analysis was performed to establish their inheritance patterns. Biochemical and cerebral magnetic resonance spectroscopy findings were also evaluated in individuals with pathogenic GAMT variants.
Results: Pathogenic biallelic GAMT variants were identified in two unrelated families. Patient 1 harbored the homozygous nonsense variant NM_000156.6:c.134G > A (p.Trp45Ter), whereas Patient 2 carried a novel homozygous four-base-pair deletion, NM_000156.6:c.373_376del (p.Pro125ThrfsTer35), predicted to result in premature protein truncation. Both variants were absent from the population databases examined and were classified as pathogenic according to ACMG/AMP criteria. Sanger sequencing confirmed homozygosity in the affected individuals and heterozygosity in their parents, consistent with autosomal recessive inheritance. Both patients exhibited global developmental delay, intellectual disability, severe speech impairment, behavioral/autistic features, and a history of seizures. Elevated plasma GAA concentrations and reduced cerebral creatine levels further supported the diagnosis of GAMT deficiency.
Conclusions: This study expands the molecular spectrum of GAMT-related disease by identifying a novel pathogenic frameshift variant and provides additional clinical and biochemical characterization of GAMT deficiency in Iranian individuals with ID. The findings highlight the importance of considering GAMT deficiency among the potentially treatable causes of unexplained intellectual disability, particularly when neurodevelopmental manifestations are accompanied by biochemical evidence of disturbed creatine metabolism. Early molecular and biochemical recognition may facilitate appropriate clinical management and genetic counseling.
Related
- How often do Australian government-funded interventional trials exclude adults with intellectual disability? A retrospective registry analysis of ANZCTR records, 2022-2024.
- An adaptive technical and behavioral approach for biomarker acquisition in autism with intellectual disability
- Nutraceutical, Nutritional and Phytotherapeutic Interventions for Neuropsychiatric Disorders Associated with Intellectual Disability: Mechanisms and Clinical Evidence
- Exome-wide rare variant genetic load is associated with cognition, intellectual disability and psychiatric disorders in population-based cohorts
- Primary aldosteronism with intellectual disability associated with CACNA1H and PPP2R5D mutations: a case report with review of literature
BibTeX
@article{hashemi2026identification,
title = {{Identification of two pathogenic guanidinoacetate methyltransferase variants in patients with intellectual disability: clinical and molecular insights}},
author = {Seyyed Reza Hashemi and AbdolAzim Nejatizadeh and Mohammad Hasan Sheikhha and Ali Reza Moayedi and Abbas Daneshipour and Shokouh Rajabi Firoozabadi and Seyed Ahmad Mohammadi and Seyed Mehdi Kalantar},
journal = {Molecular Genetics and Metabolism Reports},
year = {2026},
month = oct,
doi = {10.1016/j.ymgmr.2026.101374},
url = {https://doi.org/10.1016/j.ymgmr.2026.101374},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Identification of two pathogenic guanidinoacetate methyltransferase variants in patients with intellectual disability: clinical and molecular insights
AU - Seyyed Reza Hashemi
AU - AbdolAzim Nejatizadeh
AU - Mohammad Hasan Sheikhha
AU - Ali Reza Moayedi
AU - Abbas Daneshipour
AU - Shokouh Rajabi Firoozabadi
AU - Seyed Ahmad Mohammadi
AU - Seyed Mehdi Kalantar
PY - 2026
DA - 2026/10/17
JO - Molecular Genetics and Metabolism Reports
DO - 10.1016/j.ymgmr.2026.101374
UR - https://doi.org/10.1016/j.ymgmr.2026.101374
AB - Background: Intellectual disability (ID) is a genetically heterogeneous neurodevelopmental disorder with diverse underlying causes. Guanidinoacetate methyltransferase (GAMT) deficiency is a rare autosomal recessive disorder of creatine biosynthesis characterized by cerebral creatine depletion and accumulation of guanidinoacetate (GAA), resulting in a spectrum of neurodevelopmental manifestations, including intellectual disability. This study aimed to investigate the molecular basis of ID in individuals with suspected genetic etiologies and to characterize pathogenic GAMT variants. Methods: Whole-exome sequencing (WES) was performed in 50 unrelated Iranian individuals with idiopathic ID. Variants were prioritized based on population allele frequency, predicted functional impact, and genotype–phenotype correlation. Candidate variants were confirmed by Sanger sequencing, and segregation analysis was performed to establish their inheritance patterns. Biochemical and cerebral magnetic resonance spectroscopy findings were also evaluated in individuals with pathogenic GAMT variants. Results: Pathogenic biallelic GAMT variants were identified in two unrelated families. Patient 1 harbored the homozygous nonsense variant NM_000156.6:c.134G > A (p.Trp45Ter), whereas Patient 2 carried a novel homozygous four-base-pair deletion, NM_000156.6:c.373_376del (p.Pro125ThrfsTer35), predicted to result in premature protein truncation. Both variants were absent from the population databases examined and were classified as pathogenic according to ACMG/AMP criteria. Sanger sequencing confirmed homozygosity in the affected individuals and heterozygosity in their parents, consistent with autosomal recessive inheritance. Both patients exhibited global developmental delay, intellectual disability, severe speech impairment, behavioral/autistic features, and a history of seizures. Elevated plasma GAA concentrations and reduced cerebral creatine levels further supported the diagnosis of GAMT deficiency. Conclusions: This study expands the molecular spectrum of GAMT-related disease by identifying a novel pathogenic frameshift variant and provides additional clinical and biochemical characterization of GAMT deficiency in Iranian individuals with ID. The findings highlight the importance of considering GAMT deficiency among the potentially treatable causes of unexplained intellectual disability, particularly when neurodevelopmental manifestations are accompanied by biochemical evidence of disturbed creatine metabolism. Early molecular and biochemical recognition may facilitate appropriate clinical management and genetic counseling.
SN - 2214-4269
ER -